Form 4: United Therapeutics COO Exercises Options, Sells Shares

United Therapeutics President and COO Michael Benkowitz exercised stock options and sold the resulting shares totaling 7,875, pursuant to a pre-arranged 10b5-1 trading plan.

Summary

• Michael Benkowitz, President and COO of United Therapeutics Corp, exercised 7,875 stock options at an exercise price of $146.03 per share on January 5, 2026.
• Immediately following the exercise, Benkowitz sold all 7,875 shares of Common Stock acquired.
• The sales were executed in multiple trades at weighted average prices ranging from $480.6832 to $494.2724 per share.
• These transactions were carried out under a pre-arranged Rule 10b5-1 trading plan established on June 3, 2025.
• After these transactions, the trust beneficially owned by Benkowitz holds 52,315 stock options and no common stock from these specific transactions. Benkowitz also directly owns 2,648 shares of Common Stock.

Sentiment

Score: 6

Explanation: The transaction is largely neutral as it was pre-planned under a 10b5-1 plan. While insider selling can be seen negatively, the pre-planned nature and significant profit from option exercise mitigate this. The high sale price reflects a strong stock performance.

Positives

• The transactions were executed under a Rule 10b5-1 trading plan, indicating pre-planned sales and reducing concerns about opportunistic insider trading.
• The sale prices for the common stock were significantly higher than the option exercise price, indicating a substantial gain for the reporting person.
• The company's stock traded at a high price range ($480.68 to $494.27) on the transaction date.

Negatives

• An insider, the President and COO, sold a significant number of shares, which can sometimes be interpreted as a lack of confidence, although mitigated by the 10b5-1 plan.

Future Outlook

NA

Industry Context

NA

Related Party Transactions

• The transactions involved shares held indirectly by a trust beneficially owned by the reporting person, with family members as beneficiaries.

Stakeholder Impact

• Shareholders: The sale by a key executive, even if pre-planned, might be viewed with slight caution, but the 10b5-1 plan reduces concerns about opportunistic selling. The high sale price reflects positive market valuation.

Key Dates

Recommendation

The filing details a routine, pre-planned insider transaction under a Rule 10b5-1 plan, which typically does not signal a change in the company's fundamental outlook. While an executive selling shares might raise questions, the structured nature of the sale and the significant profit realized from option exercise suggest a personal financial management decision rather than a bearish view on the company. Therefore, the filing itself does not provide new information to warrant a change in investment stance; a 'hold' recommendation is appropriate, pending further fundamental analysis of the company's performance and prospects.

Keywords

United Therapeutics, UTHR, Form 4, Insider Trading, Stock Options, Rule 10b5-1, Executive Compensation, Share Sale, Michael Benkowitz, Biotechnology